Press "Enter" to skip to content

Last of Cost-Effectiveness Data for Expensive Drugs Paid by Medicare

Share this:

Axios writes of a JAMA Network Open report that found nearly $50 billion or a third of Medicare Part D costs in 2016 were for drugs with absent cost-effectiveness analyses. The lack of a quality analysis that weighs the relative cost with outcomes of these drugs may create hurdles toward efforts aimed at addressing drug spending in terms of value.

Read more:

Share this: